<DOC>
	<DOCNO>NCT01719341</DOCNO>
	<brief_summary>Allogeneic haematopoietic stem cell transplantation ( HSCT ) potentially curative therapy patient haematological non-haematological disorder . However , one major limit factor transplantation inability identify suitable HLA-matched donor . Development cost-effective clinically efficacious alternative HLA-identical sibling unrelated donor transplantation would significantly expand availability allogeneic HSCT patient Singapore . Preliminary result indicate use high dose post-transplant cyclophosphamide ( Cy ) graft versus host disease ( GVHD ) prophylaxis haplo-identical allogeneic HSCT associate low incidence GVHD low treatment relate toxicity . We propose phase II clinical trial ass efficacy haplo-identical allogeneic transplantation protocol use high dose post-transplant Cy treatment patient haematological disorder . A non-myeloablative protocol ( Fludarabine-low dose cyclophosphamide-TBI ) use patient bone marrow failure syndromes indolent lymphoid disease . In view high relapse risk patient myeloid malignancy , patient treat reduced intensity condition regimen ( Fludarabine-Busulphan ) . The primary end-point study overall survival one year . Economic cost haplo-identical transplantation , well treatment timeline record compare form unrelated donor allogeneic transplantation ( umbilical cord blood transplantation unrelated HLA-matched adult donor ) . Immunological reconstitution patient follow haplo-transplantation analyse data utilized guide future immunotherapy strategies post-transplantation . One year survival non-myeloablative haploidentical stem cell transplantation inferior observe non-myeloablative volunteer unrelated donor unrelated cord blood haematopoietic stem cell transplantation .</brief_summary>
	<brief_title>Study Non-Myeloablative Haplo-identical Haematopoietic Stem Cell Transplantation Patients With Haematological Malignancies Acquired Aplastic Anaemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>Patient Selection Inclusion criteria 1 . Age 70 year old 18 year 2 . Absence HLA fully compatible relate donor 3 . Need urgent transplantation , define within 8 week referral transplant centre absence HLAcompatible VUD search international registry . Patients HLAcompatible VUD whose donor consider transplantation centre unsuitable also eligible . 4 . Informed consent . Disease inclusion criterion : In general encompasses haematological disorder volunteer unrelated donor ( UD ) transplant clinically indicate . 1 . Acute , chronic leukaemia myelodysplastic syndrome allogeneic transplantation consider best treatment option . . Acute myeloid leukaemia ( AML ) . In first complete remission ( CR1 ) one follow characteristic : 1 . High risk cytogenetic molecular alteration ( e.g . ( 9 ; 22 ) , deletion 7/7q , monosomy 5 del ( 5q ) , 3q26 alteration , complex karyotype [ 3 anomaly ] , p53 alteration , 11q23 especially ( 6 ; 11 ) abnormality , FLT3 ITD , monosomal karyotype . 2 . Leukocytes diagnosis &gt; 50 x109/l ( except case good prognosis molecular rearrangement leukocytes &gt; 100 x 109/l ) b. Myelodysplastic syndromes1 . International Prognosis Index ( IPSS ) 1 ( intermediate group 2 high risk ) 2 . IPSS 0 0.5 presence cytopenia require treatment . c. Therapy relate AML MDS first CRd . AML MDS second ( CR2 ) subsequent CRe . Ph'positive chronic myeloid leukaemia . In first chronic phase refractory and/or intolerance tyrosine kinase inhibitor clearly demonstrate ii . In second chronic phase 2 . Acute lymphoblastic leukaemia ( ALL ) . In CR1 one follow characteristic : . Very high risk chromosome molecular alteration ( e.g . ( 9 ; 22 ) , ( 4 ; 11 ) , complex karyotype adult , bcr/abl rearrangement , MLL rearrangement ) ii . Slow response induction treatment define presence &gt; 10 % blast bone marrow day 14 induction treatmentiii . Adults age &gt; 30 yearsiv . Adults B ALL cell line number leukocytes diagnosis &gt; 25 x 109/L T ALL cell line number leukocytes diagnosis &gt; 100X109/Lb . In CR2 subsequent CR 3 . NonHodgkin 's lymphomaa . Follicular NHL : second subsequent complete partial remissionb . Mantle cell NHL : second subsequent complete partial remissionc . High grade NHL : second complete good partial remission 4 . Hodgkin 's diseasea . second subsequent complete partial remission 5 . Chronic lymphocytic leukaemia . a. second subsequent remissionb . adverse risk prognostic feature first remission 6 . Acquired Aplastic Anaemia 7 . Myelofibrosis Lille score high , Cervantes scorehigh 8 . Other haematological malignancy UD HSCT indicate 1 . Patients available 78/8 HLAA , B , C , DRB1 match sibling donor 78/8 unrelated bone marrow donor 2 . Availability suitable UCB unit/s eligible UCB transplant 3 . ECOG performance status worse 2 4 . Cardiac insufficiency require treatment , symptomatic coronary artery disease LVEF le 35 % . 5 . Hepatic disease , total bilirubin great 2 time upper limit normal AST &gt; 5 time upper limit normal . 6 . Severe hypoxaemia , pO2 &lt; 70 mm Hg , decrease DLCO &lt; 50 % predict ; mild hypoxemia , pO2 &lt; 80 mm Hg severely decrease DLCO &lt; 50 % predict . 7 . Impaired renal function ( creatinine &gt; 2 time upper limit normal creatinine clearance &lt; 50 % age , gender , weight ) . 8 . Previous irradiation precludes safe administration additional dose 200 cGy total body irradiation ( TBI ) . 9 . HIV positive patient . 10 . Female patient pregnant breast feeding due risk foetus condition regimen potential risk nurse infant . 11 . Life expectancy severely limited disease disease indication transplant 12 . Serious concurrent uncontrolled infection e.g . active tuberculosis , mycoses viral infection 13 . Serious psychiatric/ psychological disorder 14 . Absence /inability provide inform consent 15 . Patients acute leukaemia &gt; 5 % bone marrow blast 16 . Intermediate high grade NHL , mantle cell NHL Hodgkin 's disease refractory salvage therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>